| Objective To observe the expression of serum osteoprotegerin (OPG) and soluble receptor activator of nuclear factor-κB ligand (sRANKL) levels in patients with chronic heart failure (CHF), and to explore the relationship between those and osteoporosis in CHF patients, providing value for the diagnose and intervention of CHF patients with osteoporosis. Methods CHF patients hospitalized from January 2020 to August 2021 were selected to detect serum OPG and sRANKL and bone mineral density (BMD) levels. They were divided into non-osteoporosis group and osteoporosis group according to bone mass. The serum OPG and sRANKL levels and their correlation with bone mineral density were compared between the two groups. The diagnostic value of OPG and sRANKL levels in CHF patients with osteoporosis was analyzed. Results (1) Serum levels of OPG and sRANKL in CHF patients with osteoporosis were higher than those in CHF patients without osteoporosis, and the differences were statistically significant (P<0.001). (2) Serum OPG and sRANKL levels were negatively correlated with BMD in CHF patients (r=-0.595/-0.458, P<0.001). (3) Serum OPG and sRANKL were risk factors for osteoporosis in CHF patients (OR=1.004, P=0.005; OR=1.061, P=0.011). (4) ROC curve was used to analyze the predictive value of serum OPG and sRANKL levels on osteoporosis in CHF patients. The area under ROC curve (AUC) was 0.761 and 0.703, respectively (P<0.001). When OPG=246.93, the highest Youden index was 0.431, which had the greatest diagnostic value for osteoporosis in CHF. The sensitivity and specificity were 0.769 and 0.662, respectively. When sRANKL=20.275, the Youden index was 0.385, and the sensitivity and specificity were 0.635 and 0.750, respectively, which had the greatest diagnosis value for osteoporosis in CHF. Conclusion Monitoring serum OPG and sRANKL levels may be helpful to detect osteoporosis in patients with CHF, providing an important reference for clinical diagnosis and treatment of CHF combined with osteoporosis. |